Clinical Trials in Detroit

Showing 2601-2620 of 9,449 trials

Safety Study of XT-150 in Participants With ALS

NCT06704347

This is a Phase 1, open-label, multi-center safety study of XT-150 in adult participants with Amyotrophic Lateral Sclerosis (ALS). Participants providing informed consent and meeting all study eligibility criteria will be enrolled in the study and will receive a single injection of XT-150 at the Baseline visit. Follow-up visits will occur over 180 days (6 months) after the injection. 8 participants (4 participants per dose level) will be enrolled sequentially in up to 2 ascending, single dose cohorts: Cohort 1: 1.5 mg XT-150 Cohort 2: 4.5 mg XT-150

Amyotrophic Lateral Sclerosis (ALS)

Xalud Therapeutics, Inc.8 participantsStarted Nov 2025

Phoenix, Arizona, United States • Baltimore, Maryland, United States • Boston, Massachusetts, United States +1 more locations

RECRUITINGNA< 1 mile

S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

NCT03723928

This randomized research trial studies how well serum tumor marker directed disease monitoring works in monitoring patients with hormone receptor positive Her2 negative breast cancer that has spread to other places in the body. Using markers to prompt when scans should be ordered may be as good as the usual approach to monitoring disease.

Anatomic Stage IV Breast Cancer AJCC v8Estrogen Receptor PositiveHER2/Neu Negative+3 more

SWOG Cancer Research Network739 participantsStarted Sep 2018

Anchorage, Alaska, United States • Anchorage, Alaska, United States • Anchorage, Alaska, United States +720 more locations

Safety Study of XT-150 in Participants With ALS

S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

Find Trials by Condition in Detroit

Long Term Follow-up of HPV Vaccine in HIV (CTN 236)

Prophylactic Application of an Incisional Wound Vac to Prevent Wound Complications in Obese Spine Surgery Patients

Amivantamab in Adenoid Cystic Carcinoma

CIPN Decision Aid for the Improvement of Chemotherapy Decision Making in Patients With Breast Cancer

REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma

Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs

Cardiac Rehabilitation to Improve Breast Cancer Outcomes

A Study to Evaluate the Efficacy and Safety of DC-806 in Participants With Moderate to Severe Plaque Psoriasis

Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation

AB-1002 in Patients With Class III Heart Failure

Trial of the Impact of Sibeprenlimab on Immunoglobulin A Nephropathy Kidney Tissue

Study to Evaluate the Efficacy of a Probiotic in Infantile Colic Symptoms Relief

Long-term Follow-up of Subjects With Transfusion-Dependent β-Thalassemia (TDT) Treated With Ex Vivo Gene Therapy

Extracellular RNA Markers of Liver Disease and Cancer

Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD

The ME&MG Digital Solution for Autonomous Assessment of Myasthenia Gravis

Effect of Tusamitamab Ravtansine on QTc Interval in Participants With Metastatic Solid Tumors

Study of WAL0921 in Patients With Glomerular Kidney Diseases